AIM: To ensure that the Community Pharmacy-Based Anticoagulation Management Service (CPAMS) in New Zealand has continued to deliver a high standard of anticoagulant care as the service has grown to provide warfarin supervision to over 4,000 patients. METHODS: A clinical audit of patients managed through CPAMS over two years from 1 January, 2013. Anticoagulant control was assessed by measuring the time in therapeutic range (TTR), proportion of high and low INR results and incidence of reported bleeds. Compliance with the service was evaluated by monitoring the frequency of testing and the interval between tests. RESULTS: There has been only a modest change in the TTR from 76.4% to 74% during the audit period, despite the growth in patient numbers from 850 to 4,350. There was no change in the proportion of INR results above 4.0. Bleeding was reported in less than 4% of visits and 82% of bleeds were minor. 75% of patients attended for INR testing on the expected date, and only 3.3% were more than 2 weeks overdue. The interval between tests remained constant at approximately 19 days. CONCLUSION: CPAMS provides safe reliable anticoagulant care with a consistently high level of anticoagulant control.
AIM: To ensure that the Community Pharmacy-Based Anticoagulation Management Service (CPAMS) in New Zealand has continued to deliver a high standard of anticoagulant care as the service has grown to provide warfarin supervision to over 4,000 patients. METHODS: A clinical audit of patients managed through CPAMS over two years from 1 January, 2013. Anticoagulant control was assessed by measuring the time in therapeutic range (TTR), proportion of high and low INR results and incidence of reported bleeds. Compliance with the service was evaluated by monitoring the frequency of testing and the interval between tests. RESULTS: There has been only a modest change in the TTR from 76.4% to 74% during the audit period, despite the growth in patient numbers from 850 to 4,350. There was no change in the proportion of INR results above 4.0. Bleeding was reported in less than 4% of visits and 82% of bleeds were minor. 75% of patients attended for INR testing on the expected date, and only 3.3% were more than 2 weeks overdue. The interval between tests remained constant at approximately 19 days. CONCLUSION: CPAMS provides safe reliable anticoagulant care with a consistently high level of anticoagulant control.
Authors: Kebede Beyene; Amy Hai Yan Chan; Naga Sai Trisha Bandreddi; Reihaneh Bassam Tabar; Emily Moyle; Sokunvattey Nath; Nianwen Wang; Jeff Harrison Journal: Int J Clin Pharm Date: 2020-08-18
Authors: Samantha J Ingram; Charlotte L Kirkdale; Sian Williams; Elaine Hartley; Susan Wintle; Valerie Sefton; Tracey Thornley Journal: BMC Health Serv Res Date: 2018-02-07 Impact factor: 2.655